TABLE IV.
Reasons for all reported dose reductions in 33 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in Manitoba approved for treatment with ibrutinib between August 2014 and March 2017
| Reason | Patients affected [n (%)] | Duration (days) | ||
|---|---|---|---|---|
| Median | IQR | Range | ||
| Musculoskeletal problem | 17 (28.81) | 161.00 | 224.00 | 0–617 |
| Cytopenia | 11 (18.64) | 65.00 | 224.00 | 4–373 |
| Infection | 9 (15.5) | 112.00 | 78.00 | 1–599 |
| Cardiac effects | 6 (10.17) | 39.50 | 98.00 | 3–599 |
| Gastrointestinal effects | 6 (10.17) | 63.00 | 86.00 | 22–206 |
| Bruising and bleeding | 3 (5.08) | 13.00 | 589.00 | 10–599 |
| Medication interaction | 3 (5.08) | 7.00 | 1.00 | 6–7 |
| Neurologic effects | 3 (5.08) | 123.00 | 288.00 | 45–333 |
| Hair and nail effects | 1 (1.69) | 266.00 | 0 | 266–266 |
IQR = interquartile range.